multivariate regression with l1 regularization (lasso) Search Results



N/A
A patent has been filed with the USPTO for this product. The USPTO application number is 63/663,524. This product can be used in lipid nanoparticle formulations as a cationic lipid. pKa=6.45 (measured by TNS)
  Buy from Supplier

90
Adjuvance oxaliplatin
Kaplan-Meier curve for local recurrence-free survival (LRC) at 5 years with <t>oxaliplatin</t> in adjuvance. LRC with ≤6 cycles =81% vs. LCR with >6 cycles =96.5% (P=0.012).
Oxaliplatin, supplied by Adjuvance, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multivariate+regression+with+l1+regularization+(lasso)/oxaliplatin/pmc06087854-199-10-12
Average 90 stars, based on 1 article reviews
oxaliplatin - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

86
Glaxo Smith v503
Kaplan-Meier curve for local recurrence-free survival (LRC) at 5 years with <t>oxaliplatin</t> in adjuvance. LRC with ≤6 cycles =81% vs. LCR with >6 cycles =96.5% (P=0.012).
V503, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multivariate+regression+with+l1+regularization+(lasso)/v503/10__24875_slash_aidsrev__19000114-160-20-56
Average 86 stars, based on 1 article reviews
v503 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

90
CEM Corporation global multivariate l1 distance l411
Kaplan-Meier curve for local recurrence-free survival (LRC) at 5 years with <t>oxaliplatin</t> in adjuvance. LRC with ≤6 cycles =81% vs. LCR with >6 cycles =96.5% (P=0.012).
Global Multivariate L1 Distance L411, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multivariate+regression+with+l1+regularization+(lasso)/global+multivariate+l1+distance+l411/pm31559905-106-9-18
Average 90 stars, based on 1 article reviews
global multivariate l1 distance l411 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

99
STATA Corporation e b l m s f v f r j l 1 multivariate linear regression
Kaplan-Meier curve for local recurrence-free survival (LRC) at 5 years with <t>oxaliplatin</t> in adjuvance. LRC with ≤6 cycles =81% vs. LCR with >6 cycles =96.5% (P=0.012).
E B L M S F V F R J L 1 Multivariate Linear Regression, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multivariate+regression+with+l1+regularization+(lasso)/STATA+1%2E0/pm18374300-38-55-85
Average 99 stars, based on 1 article reviews
e b l m s f v f r j l 1 multivariate linear regression - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

86
Affibody multivalent immune checkpoint inhibitor abd 2 tri zpd l1
Kaplan-Meier curve for local recurrence-free survival (LRC) at 5 years with <t>oxaliplatin</t> in adjuvance. LRC with ≤6 cycles =81% vs. LCR with >6 cycles =96.5% (P=0.012).
Multivalent Immune Checkpoint Inhibitor Abd 2 Tri Zpd L1, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multivariate+regression+with+l1+regularization+(lasso)/2+abd+checkpoint+immune+inhibitor+l1+multivalent+tri+zpd/pm40852789-131-22-8
Average 86 stars, based on 1 article reviews
multivalent immune checkpoint inhibitor abd 2 tri zpd l1 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier


N/A
CRISPR/Cas9 KO Plasmids consists of Multimerin-1-specific 20 nt guide RNA sequences derived from the GeCKO (v2) library. For CRISPR gene knockout, gRNA sequences direct the Cas9 protein to induce a site-specific double strand break (DSB)
  Buy from Supplier

Image Search Results


Kaplan-Meier curve for local recurrence-free survival (LRC) at 5 years with oxaliplatin in adjuvance. LRC with ≤6 cycles =81% vs. LCR with >6 cycles =96.5% (P=0.012).

Journal: Journal of Gastrointestinal Oncology

Article Title: The value of oxaliplatin in the systemic treatment of locally advanced rectal cancer

doi: 10.21037/jgo.2018.06.02

Figure Lengend Snippet: Kaplan-Meier curve for local recurrence-free survival (LRC) at 5 years with oxaliplatin in adjuvance. LRC with ≤6 cycles =81% vs. LCR with >6 cycles =96.5% (P=0.012).

Article Snippet: The univariate and multivariate analyses showed that the dose of oxaliplatin in adjuvance (postoperative) greater than 6 cycles was positively associated with local recurrence-free survival (LRC) at 5 years (P=0.012, ) and with overall survival (OS) at 5 years (P=0.048, ).

Techniques:

Kaplan-Meier curve for overall survival (OS) at 5 years with oxaliplatin in adjuvance. OS with ≤6 cycles =72% vs. OS with >6 cycles =81% (P=0.048).

Journal: Journal of Gastrointestinal Oncology

Article Title: The value of oxaliplatin in the systemic treatment of locally advanced rectal cancer

doi: 10.21037/jgo.2018.06.02

Figure Lengend Snippet: Kaplan-Meier curve for overall survival (OS) at 5 years with oxaliplatin in adjuvance. OS with ≤6 cycles =72% vs. OS with >6 cycles =81% (P=0.048).

Article Snippet: The univariate and multivariate analyses showed that the dose of oxaliplatin in adjuvance (postoperative) greater than 6 cycles was positively associated with local recurrence-free survival (LRC) at 5 years (P=0.012, ) and with overall survival (OS) at 5 years (P=0.048, ).

Techniques: